Tempus Introduces xM to Assess Minimal Residual Disease (MRD) in Patients with Colorectal Cancer (CRC) for Research Use Only
Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions.
- Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of a novel MRD assay, xM, to its comprehensive testing solutions.
- The tumor-naïve plasma based test is available for research use only to detect circulating tumor DNA (ctDNA) in the blood of patients with early stage CRC after surgery.
- xM is a liquid biopsy approach to MRD assessment, where no baseline tumor tissue is required.
- “Colorectal cancer is the second leading cause of cancer-related deaths worldwide,1 and surgical intervention alone may not be curative for all patients.